Navigation Links
Nile Therapeutics Reports 2010 Third Quarter Financial Results
Date:11/12/2010

SAN MATEO, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for therapeutics for cardiovascular disease, today announced its third quarter financial results for 2010.

Financial ResultsFor the three months ended September 30, 2010, Nile reported a net loss of approximately $1.8 million, or $0.05 per share, compared to a net loss of approximately $2.0 million, or $0.08 per share, during the third quarter of 2009. Weighted-average shares outstanding for the third quarter were 34.6 million.

Net cash used in operating activities in the third quarter of 2010 was approximately $1.1 million. As of September 30, 2010, Nile had cash and cash equivalents of approximately $4.4 million compared to approximately $3.2 million as of December 31, 2009.

Qualifying Therapeutic Discovery Project GrantNile was recently awarded a $244,479 grant under the Internal Revenue Service's Qualifying Therapeutic Discovery Project program, which was established under the U.S. Patient Protection and Affordable Care Act of 2010.  The Company expects to receive the grant funds prior to the end of 2010.

Update on CD-NPOn November 2, Nile announced that CD-NP met the primary end-point, safety and tolerability, in an open-label, single-blind, placebo-controlled Phase 2 study of 77 patients with acute decompensated heart failure (ADHF) and renal dysfunction. Additionally, secondary analyses demonstrated favorable effects of CD-NP on renal function.

An infusion of CD-NP for up to 72 hours at doses of 1.25 and 2.5 ng/kg/min appeared to be well tolerated.  A dose-dependent effect on blood pressure was observed, with minimal or mild blood pressure reduction at 1.25 and 2.5 ng/kg/min, and moderate blood pressure reduction at 3.75 ng/kg/min.  Dose escalation was limited by
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds that the ... will remain relatively stagnant at a value of ... that percutaneous coronary intervention (PCI) volumes are growing faster in ... such as the United States and ... driven by the increase in penetration of PCI procedures relative ...
(Date:7/22/2014)... WASHINGTON , July 22, 2014 ... "Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds ... (MS) patients currently treated with Biogen Idec,s ... experienced flushing and/or gastrointestinal events while on ... currently experiencing these side effects, signifying either ... management of such events. In the end, ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3
... Pa., Dec. 29, 2010 Endo Pharmaceuticals (Nasdaq: ... and Drug Administration (FDA) has approved FORTESTA Gel for ... known as hypogonadism. Symptoms associated with Low T include ... of energy, mood depression, regression of secondary sexual characteristics ...
... Dr. David Samadi, the Vice Chairman, Department of Urology, ... The Mount Sinai Medical Center in New York City, ... completion of six successful robotic prostate cancer treatment ... three of which were televised live, Samadi demonstrated his ...
Cached Medicine Technology:Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 2Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 3Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 4Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 5Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone 6Robotic Surgery Expert Dr. David Samadi, MD Determines Live Robotic Prostate Cancer Surgeries During Israel Trip A Success 2Robotic Surgery Expert Dr. David Samadi, MD Determines Live Robotic Prostate Cancer Surgeries During Israel Trip A Success 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 According to ... Health care, Automobile, Aerospace & Defense, Marine and Mining) ... Middle East, and Rest of the world) - Forecast ... is expected to grow at a CAGR 8.00% to ... Europe is estimated to grow at a CAGR of ...
(Date:7/22/2014)... Dimension One Spas’ retailers across the ... all models during the “Let’s Take This Outside” Summer ... http://www.d1spas.com/financing for more information and to apply. ... offers a wide variety of outdoor hot tubs with ... music, customizable massage, and personal controls. , ...
(Date:7/22/2014)... July 22, 2014 (HealthDay News) -- People who suffer ... for a rise in blood pressure, a new study ... health problems and even early death, but few studies ... may be one of the causes, according to the ... people who had been separated or divorced for about ...
(Date:7/22/2014)... has received a five-year, $3 million grant to ... neglect and maltreatment during childhood leave molecular marks ... life. , The Center for Biomarker Research and ... in collaboration with Duke University School of Medicine, ... by the National Institutes of Health, National Institute ...
(Date:7/22/2014)... July 22, 2014 BlogHer, Inc. ... women, this year celebrates its tenth anniversary where it ... of attendees, including community leaders from the new women’s ... every consumer vertical, will converge in San Jose this ... and a “selfiebration” of social technology. , BlogHer’s ...
Breaking Medicine News(10 mins):Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2Health News:VCU receives grant to study molecular marks left by childhood adverse experiences 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 3Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 4
... Calif., Aug. 6 IRIDEX Corporation (NASDAQ: IRIX ) today ... the market closes on Thursday, August 13, 2009. ... call with the investment community at 5:00 p.m. Eastern Time ... discuss the results of the quarter and other business developments. , ...
... ,Is the White House looking to intimidate and silence opponents?, asks FRC,s ... In a web video released today, Family Research Council ( FRC ... send the White House any email or health care messages deemed "fishy." ... ) , , Family Research Council President ...
... OAK BROOK, Ill., Aug. 6 SedationFacts.org, ... gastroenterology fellows, announces enhancements to the sedation administration standards ... administration information and reliable links to other state resources. ... regulations governing sedation administration by nursing personnel vary from ...
... on the way for anyone who has ever gotten lost ... is in the form of health-care signage symbols being developed ... other U.S. universities. These symbols will be tested this ... of surveys taken among the populations in three Midwestern cities, ...
... viral, bacterial infections, study finds , THURSDAY, Aug. ... appears able to identify people who,ve been exposed to ... flu, even before symptoms develop. , In a study ... a live cold virus, respiratory syncytial virus or influenza ...
... EXTON, Pa., Aug. 6 ViroPharma Incorporated (Nasdaq: VPHM ... clinical trial for NTCD (non-toxigenic Clostridium difficile ), a novel ... NTCD contains the spores of a non-toxin producing strain of ... "Colonization of the large bowel with non-toxin producing strains of ...
Cached Medicine News:Health News:White House Launches 'Fishy' Expedition 2Health News:Sedationfacts.org Enhances State-Specific Site Content, Making Regional Sedation Administration Standards and Regulations Quick and Easy to Find and Use 2Health News:Sedationfacts.org Enhances State-Specific Site Content, Making Regional Sedation Administration Standards and Regulations Quick and Easy to Find and Use 3Health News:Sedationfacts.org Enhances State-Specific Site Content, Making Regional Sedation Administration Standards and Regulations Quick and Easy to Find and Use 4Health News:UC design research points the way so you won't get lost at the hospital 2Health News:UC design research points the way so you won't get lost at the hospital 3Health News:UC design research points the way so you won't get lost at the hospital 4Health News:Cold, Flu or Pneumonia? Answer May Lie in Blood Test 2Health News:ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program 2Health News:ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program 3Health News:ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program 4
... is designed for arthroscopic or open suturing ... It features heavy-gauge suture hooks and the ... hooks allow precise suture placement in otherwise ... System is for use with #2/0 to ...
Suture Cutter, 15 Up Curve...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
...
Medicine Products: